{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:16:00Z","timestamp":1777958160654,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81570884, 81770961"],"award-info":[{"award-number":["81570884, 81770961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the SMC-ChenXing Yong Scholar Program","award":["2016, Class A"],"award-info":[{"award-number":["2016, Class A"]}]},{"name":"the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant","award":["20152223"],"award-info":[{"award-number":["20152223"]}]},{"name":"Innovation Fund for Translational Medicine","award":["15ZH1005"],"award-info":[{"award-number":["15ZH1005"]}]},{"name":"Ph.D. Programs Foundation of Shanghai JiaoTong University School of Medicine","award":["BXJ201834"],"award-info":[{"award-number":["BXJ201834"]}]},{"name":"Innovative research team of high-level local universities in Shanghai","award":["Department of Ophthalmology, Shanghai Ninth People Hospital"],"award-info":[{"award-number":["Department of Ophthalmology, Shanghai Ninth People Hospital"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7\u2009months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the <jats:italic>NUT<\/jats:italic> gene.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>Here, we described a patient who initially presented with epiphora, and an orbit involved NMC. In addition, we for the first time demonstrated that local radiotherapy combined with tyrosine kinase inhibitor <jats:bold>(<\/jats:bold>TKI) could significantly inhibit tumor progression in orbital involvement by NMC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our study for the first time described an orbit involved NMC patient initially presented with epiphora. In addition, we provided an alternative to the management of orbit involved NMC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13000-019-0922-1","type":"journal-article","created":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T04:53:37Z","timestamp":1578113617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Peiwei","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuandi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renbing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yefei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,4]]},"reference":[{"key":"922_CR1","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1002\/cncr.30242","volume":"122","author":"NG Chau","year":"2016","unstructured":"Chau NG, Hurwitz S, Mitchell CM, et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016;122:3632\u201340.","journal-title":"Cancer"},{"key":"922_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrc3659","volume":"14","author":"C French","year":"2014","unstructured":"French C. NUT midline carcinoma. Nat Rev Cancer. 2014;14:149\u201350.","journal-title":"Nat Rev Cancer"},{"key":"922_CR3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/bjc.2014.54","volume":"110","author":"AH Beesley","year":"2014","unstructured":"Beesley AH, Stirnweiss A, Ferrari E, et al. Comparative drug screening in NUT midline carcinoma. Br J Cancer. 2014;110:1189\u201398.","journal-title":"Br J Cancer"},{"key":"922_CR4","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","volume":"18","author":"DE Bauer","year":"2012","unstructured":"Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773\u20139.","journal-title":"Clin Cancer Res"},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"E5352","DOI":"10.1073\/pnas.1703071114","volume":"114","author":"R Wang","year":"2017","unstructured":"Wang R, Cao XJ, Kulej K, et al. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. Proc Natl Acad Sci U S A. 2017;114:E5352\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/IOP.0000000000000179","volume":"31","author":"JN D\u2019Souza","year":"2015","unstructured":"D\u2019Souza JN, Notz G, Bogdasarian RN, et al. Orbital involvement by NUT midline carcinoma. Ophthalmic Plast Reconstr Surg. 2015;31:e147\u201350.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"922_CR7","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.celrep.2017.08.082","volume":"20","author":"J Bragelmann","year":"2017","unstructured":"Bragelmann J, Dammert MA, Dietlein F, et al. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Rep. 2017;20:2833\u201345.","journal-title":"Cell Rep"},{"key":"922_CR8","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1200\/JCO.2013.51.1741","volume":"34","author":"Y Gokmen-Polar","year":"2016","unstructured":"Gokmen-Polar Y, Kesler K, Loehrer PJ Sr, et al. NUT midline carcinoma masquerading as a Thymic carcinoma. J Clin Oncol. 2016;34:e126\u20139.","journal-title":"J Clin Oncol"},{"key":"922_CR9","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1200\/JCO.2010.32.7486","volume":"29","author":"M Teo","year":"2011","unstructured":"Teo M, Crotty P, O'Sullivan M, et al. NUT midline carcinoma in a young woman. J Clin Oncol. 2011;29:e336\u20139.","journal-title":"J Clin Oncol"},{"key":"922_CR10","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with Birabresib, a small-molecule inhibitor of Bromodomain and Extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36:3007\u201314.","journal-title":"J Clin Oncol"},{"key":"922_CR11","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-18-2316","volume":"79","author":"OY Revach","year":"2019","unstructured":"Revach OY, Sandler O, Samuels Y, et al. Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates Invadopodia formation in melanoma cells. Cancer Res. 2019;79:2634\u201348.","journal-title":"Cancer Res"},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41467-019-08988-3","volume":"10","author":"AV Leopold","year":"2019","unstructured":"Leopold AV, Chernov KG, Shemetov AA, et al. Neurotrophin receptor tyrosine kinases regulated with near-infrared light. Nat Commun. 2019;10:1129.","journal-title":"Nat Commun"},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1158\/1078-0432.CCR-18-2113","volume":"25","author":"DR Wahl","year":"2019","unstructured":"Wahl DR, Lawrence TS. No sugar added: a new strategy to inhibit Glioblastoma receptor tyrosine kinases. Clin Cancer Res. 2019;25:455\u20136.","journal-title":"Clin Cancer Res"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2018.5526","volume":"5","author":"XZ Chen","year":"2019","unstructured":"Chen XZ. Anlotinib for refractory advanced non-small cell lung Cancer in China. JAMA Oncol. 2019;5:116\u20137.","journal-title":"JAMA Oncol"},{"key":"922_CR15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung Cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569\u201375.","journal-title":"JAMA Oncol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0922-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-019-0922-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0922-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:06:15Z","timestamp":1609632375000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-019-0922-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,4]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1186\/s13000-019-0922-1","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,4]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for this study was obtained from the Shanghai Jiaotong University. Only non-identifiable information is presented. The patient provided signed informed consent for an Institutional Review Board-approved protocol for research use of medical records, of pathologic specimens obtained as part of routine clinical care, and publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish the clinical data was obtained from the patient before the initiation of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}